A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer
OBJECTIVES: I. Evaluate the clinical effectiveness of oral perillyl alcohol given to
patients with androgen independent metastatic prostate cancer. II. Assess the toxicity of
this treatment in these patients.
OUTLINE: Patients receive oral perillyl alcohol 4 times a day for 4 weeks. Patients continue
treatment in the absence of severe toxicity and disease progression. Patients are followed
every 3 months for survival after disease progression.
PROJECTED ACCRUAL: This study will accrue 20-40 patients in approximately 2 years.
Primary Purpose: Treatment
George Wilding, MD
University of Wisconsin, Madison
United States: Federal Government
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|
|Gundersen Lutheran Medical Center||La Crosse, Wisconsin 54601|
|Leonard C. Ferguson Cancer Center||Freeport, Illinois 61032|
|Green Bay Oncology, Ltd.||Green Bay, Wisconsin 54307-3453|
|Mercy Health System||Janesville, Wisconsin 53545|
|Meriter Hospital||Madison, Wisconsin 53715|
|Sinai Samaritan Medical Center - Milwaukee||Milwaukee, Wisconsin 53201-0342|
|North Central Oncology Associates, S.C.||Wausau, Wisconsin 54401|